Biotechnology - Biotechnology, Metabolics

Filter

Current filters:

BiotechnologyMetabolics

Popular Filters

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

27-03-2014

Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Brazil’s Cristalia gains ANVISA approval for production of biosimilar drugs

24-03-2014

The Brazilian drugmaker Cristalia has just taken another step towards its goal of producing biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBrazilCristaliaEnbrelHerceptinMetabolicsNorditropinOncologyProductionRegulationSouth America

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

NPS Pharma files BLA for Natpara in hypoparathyroidism

25-10-2013

US biotech company NPS Pharmaceuticals has submitted its Biologic License Application to the US Food…

BiotechnologyMetabolicsNatparaNorth AmericaNPS Pharmaceuticals

Orexigen updates on obesity drug filing plans

08-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) yesterday (August 7) announced its plan to…

BiotechnologyContraveEuropeFinancialMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Plandai's upcoming weight loss study primed to outperform competing trials, say analysts

05-08-2013

With a product that likely has the highest nutrient absorption rate into the bloodstream (bioavailability)…

BiotechnologyMetabolicsPhytofarePlandai BiotechnologyResearch

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

OPKO Health to acquire PROLOR Biotech in $480 million stock deal

25-04-2013

Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

FDA advisory gives thumbs down for Zogenix' Zohydro for chronic pain; EU label extension for Genzyme's Thyrogen

10-12-2012

Shares of USA-based Zogenix (Nasdaq: ZGNX) plummeted 33.5% to $1.57 in after-hours trading on Friday…

BiotechnologyEuropeGenzymeMetabolicsNeurologicalNorth AmericaPharmaceuticalRegulationSanofiThyrogenZogenixZohydro

Vivus plummets as early sales of obesity drug Qsymia disappoint

08-11-2012

US biopharma company Vivus (Nasdaq: VVUS) saw its shares plunge 24% to $11.38, after reporting third-quarter…

BiotechnologyFinancialMetabolicsPharmaceutical

AstraZeneca aligns with Regulus for microRNA therapeutics

16-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Arrowhead Research Corp improving focus, say Edison analysts

16-08-2012

Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

Low-dose Ampyra fails in multiple sclerosis study, says Acorda

15-08-2012

USA-based biotech firm Acorda Therapeutics (Nasdaq: ACOR) has announced top line results from a post-marketing…

Acorda TherapeuticsAmpyraBiotechnologyMetabolicsNeurologicalPharmaceuticalResearch

Rhythm raises $25 million to fund diabetes and obesity drugs development

14-06-2012

Rhythm raises $25 million to fund diabetes and obesity drugs development

BiotechnologyDiabetesFinancialIpsenMetabolicsResearchRhythm Pharmaceuticals

UK's Proximagen boosted by US lorcaserin news with respect to its own obesity drug candidate

14-05-2012

UK-based biotechnology firm Proximagen (AIM: PRX) saw its shares leap 20.1% to 257.5 pence, on the back…

BiotechnologyMetabolicsProximagenRegulationResearch

Arena Pharma gets positive FDA panel vote for obesity drug; prophylactic Truvada backed

11-05-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese licensing partner Eisai (TYO: 4523) got a…

Anti-viralsArena PharmaceuticalsBiotechnologyEisaiGilead ScienceslorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationTruvada

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Back to top